Edwards Lifesciences Corporation (NYSE:EW) – Research analysts at SunTrust Banks dropped their Q3 2017 earnings per share estimates for Edwards Lifesciences Corporation in a report issued on Wednesday. SunTrust Banks analyst B. Nudell now anticipates that the medical research company will post earnings per share of $0.84 for the quarter, down from their prior estimate of $0.85. SunTrust Banks has a “Buy” rating and a $14.00 price target on the stock.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The company had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $839.16 million. During the same quarter in the previous year, the firm posted $0.76 earnings per share. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: “Q3 2017 Earnings Forecast for Edwards Lifesciences Corporation Issued By SunTrust Banks (EW)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/23/q3-2017-earnings-forecast-for-edwards-lifesciences-corporation-issued-by-suntrust-banks-ew.html.

A number of other brokerages have also recently commented on EW. Royal Bank Of Canada reiterated a “buy” rating and issued a $130.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and issued a $130.00 target price (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 target price on the stock in a research report on Tuesday, July 18th. Jefferies Group LLC lifted their target price on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. Finally, BMO Capital Markets reiterated a “buy” rating and issued a $132.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. Seven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 113.08 on Monday. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.45. The company has a 50 day moving average of $111.15 and a 200 day moving average of $111.91. The company has a market cap of $23.88 billion, a PE ratio of 34.30 and a beta of 0.62.

Hedge funds and other institutional investors have recently modified their holdings of the stock. ETF Managers Group LLC purchased a new position in Edwards Lifesciences Corporation during the 2nd quarter valued at about $112,000. Shine Investment Advisory Services Inc. purchased a new position in Edwards Lifesciences Corporation during the 2nd quarter valued at about $126,000. Cornerstone Advisors Inc. lifted its position in Edwards Lifesciences Corporation by 25.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 219 shares during the period. Alexandria Capital LLC lifted its position in Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 19 shares during the period. Finally, MPS Loria Financial Planners LLC purchased a new position in Edwards Lifesciences Corporation during the 2nd quarter valued at about $140,000. 81.90% of the stock is owned by institutional investors.

In related news, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Catherine M. Szyman sold 4,681 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Insiders have sold a total of 201,161 shares of company stock worth $22,826,072 in the last ninety days. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.